RXi Acquires Exclusive License to Potentially Paradigm-Changing RNAi Delivery Technology from Advirna LLC
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
RXi Pharmaceuticals Corporation announced that it has exercised its option to an exclusive worldwide license to novel technologies from Advirna LLC to enable in vivo delivery of RNAi therapeutics. Terms of the agreement were not disclosed.
The RNAi delivery technologies licensed from Advirna encompass four distinct approaches, with the primary focus on “self-delivery” of RNAi therapeutics; that is, RNAi delivery without the use of a separate delivery vehicle.
In evaluating the Advirna technology, RXi observed that this technology delivers RNAi molecules to cells spontaneously upon direct administration, both in vitro and in vivo, without requiring a delivery vehicle or transfection formulation. RXi has reproduced this result in many cells, and has seen activity even with cells that are difficult to transfect.
Tod Woolf, Ph.D., President and Chief Executive Officer of RXi, stated, “The ability to create self-delivering RNAi therapeutics promises to provide significant competitive advantages in efficacy, toxicity, ease of administration and manufacturing costs. This unique capability is creating a great deal of interest in the scientific and business community and we believe this exciting technology could simplify clinical development of RNAi therapeutics and could position RXi to take the lead in the area of RNAi therapeutics.“
The delivery technology licensed from Advirna has been integrated into RXi’s rxRNA™ platform to create self-delivering rxRNAs (sd-rxRNAs) with the following potential advantages:
• Spontaneous cellular uptake: delivery of RNAi therapeutics without the added expense of liposomes, complexes, nanoparticles or other delivery vehicles
• Patient-friendly administration routes: subcutaneous administration to treat patients without the need of medical professional supervision
• Bio-distribution to targeted tissues: distribution of rxRNAs to certain tissues while reducing renal clearance
• Reduced side effect profiles: reduced side effects that can be associated with formulations that contain an added delivery vehicle
RXi is integrating its comprehensive delivery platform, including the new technologies licensed from Advirna, with its proprietary rxRNA™ compounds to develop a sustainable pipeline of products for unmet medical needs. RXi has a strong IP position in both RNAi compounds and delivery approaches and is using its scientific expertise in these areas to identify lead therapeutic candidates for inflammatory diseases, such as rheumatoid arthritis, diabetes, and Crohn’s disease, as well as other indications.
The RNAi delivery technologies licensed from Advirna encompass four distinct approaches, with the primary focus on “self-delivery” of RNAi therapeutics; that is, RNAi delivery without the use of a separate delivery vehicle.
In evaluating the Advirna technology, RXi observed that this technology delivers RNAi molecules to cells spontaneously upon direct administration, both in vitro and in vivo, without requiring a delivery vehicle or transfection formulation. RXi has reproduced this result in many cells, and has seen activity even with cells that are difficult to transfect.
Tod Woolf, Ph.D., President and Chief Executive Officer of RXi, stated, “The ability to create self-delivering RNAi therapeutics promises to provide significant competitive advantages in efficacy, toxicity, ease of administration and manufacturing costs. This unique capability is creating a great deal of interest in the scientific and business community and we believe this exciting technology could simplify clinical development of RNAi therapeutics and could position RXi to take the lead in the area of RNAi therapeutics.“
The delivery technology licensed from Advirna has been integrated into RXi’s rxRNA™ platform to create self-delivering rxRNAs (sd-rxRNAs) with the following potential advantages:
• Spontaneous cellular uptake: delivery of RNAi therapeutics without the added expense of liposomes, complexes, nanoparticles or other delivery vehicles
• Patient-friendly administration routes: subcutaneous administration to treat patients without the need of medical professional supervision
• Bio-distribution to targeted tissues: distribution of rxRNAs to certain tissues while reducing renal clearance
• Reduced side effect profiles: reduced side effects that can be associated with formulations that contain an added delivery vehicle
RXi is integrating its comprehensive delivery platform, including the new technologies licensed from Advirna, with its proprietary rxRNA™ compounds to develop a sustainable pipeline of products for unmet medical needs. RXi has a strong IP position in both RNAi compounds and delivery approaches and is using its scientific expertise in these areas to identify lead therapeutic candidates for inflammatory diseases, such as rheumatoid arthritis, diabetes, and Crohn’s disease, as well as other indications.
